AMPure, through a patented technology, develops, registers and places on the market new anti-acne dermocosmetic formulations – cream/booster, foam, soap.

Go to AMPure website


Bridging the gap between Basic research and Industrial development

By applying internal capabilities and exploiting funds from national and European Grants, C4T has driven proprietary early discovery projects and gained expertise in specific research areas. Hit identification and Hit to Lead programs are performed in tight collaboration with Academia partners in charge of projects molecular biology.”


PIM-1 Kinase


CB2 Receptor


(MMP-2 and MMP-9)


Tγδ linfocytes

#     Molecular Target

2    PIM-1 Kinase


Original Focused library of PIM-1 Inhibitors (Unpublished data)

  • In vitro potency (EC50 nM)
  • In vitro specificity & selectivity (wide Kinases panel)

1     CB2 Receptor


CBR Drug Discovery Platform

  • Original Focused library of CB2R modulators (WO 2014097188 A1)
    • In vitro potency (EC50 nM)
    • In vitro specificity & selectivity (CB1, FAAH, MAGL)
    • Good in silico ADME-T Profile

3     Gelatinases
       (MMP-2 and MMP-9)


Original Focused libraries of MMPs inhibitors

  • C4T 1466 Series – Non hydroxamate Zinc Binding Group
    IC50 low nanomolar range (Unpublished data)
  • C4T 1374 Series :
    IC50 pico-molar range ( WO 2008148617 A1)
  • C4T 1360 series – Selective MMP2 inhibitor
    IC50 low nanomolar range ( Bioorg.Med.Chem. 2012)


4    Tγδ linfocytes


New class of Tγδ linfocytes activators ( J.Med.Chem. 2009)

  • Thiopyrophosphate lead Series



PNR 2015-2020 PON-FSC - Bio-D Project - Oct. 2020 - current


Development of diagnostic biomarkers for precision medicine and personalized therapy


  • Beforpharma Srl
  • Center for Outcomes Research and Clinial Epidemiology s.r.l
  • CNR IMM Lecce
  • DHITECH Scarl
  • Ente Ospedaliero “Saverio de Bellis” – IRCCS
  • eResult Srl
  • EryDel Spa
  • Fondazione CER – Malattie Renali
  • Fondazione di Religione e di Culto “Casa Sollievo della Sofferenza”
  • INFN – Bari
  • Innovaal Scarl
  • Laboratorio Nazionale Consorzio Interuniversitario Biotecnologie (LNCIB)
  • Progetto Azienda Srl
  • Università del Salento
  • Università degli Studi di Bari
  • Università degli Studi di Roma “Tor Vergata”
  • Università degli Studi di Trieste
  • Università degli Studi di Urbino



Funding Scheme

Ministero dell’Istruzione, dell’Università e della Ricerca

MIUR Cluster Alisei - IVASCOMAR Project - 2013-2017
Regione Lazio II° DTB - INTERACTOMA Project - 2012-2015
Topic :
Development of new inhibitors of the bacterial cell cycle with low risk of resistance”


Funding Schemes:
Regione Lazio – Lazio Innova

VII FP (HEALTH) - FLORINASH Project - 2010-2015
Topic :
The role of intestinal microflora in NAFLD

Partnerships :

Funding Schemes:
European Union’s Research and Innovation

Regione Lazio I° DTB - NUMORECA - 2009-2012

New Modulator of Cannabinoid Receptor

Partnerships :

Funding Schemes:

Regione Lazio – Lazio Innova (ex Filas)

UNESCO - "Families First Africa" - 2007-2009
Design, synthesis and experimental check in vitro of immunogenic peptides to be used as HIV-peptides based vaccines

Partnerships :

  • University of Rome “Tor Vergata” (IT) – Prof. V.Colizzi
  • REDD (IT)
  • SARM (IT)

Funding Schemes:

MIUR FIRB - 2005-2008
Design and synthesis of a new Kinase inhibitors

Partnerships :

Funding Schemes:

Funding Schemes:
Ministero dell’Istruzione, dell’Universita e della Ricerca

MIUR (n° 2743/99) - MMPs and Tγδ inhibitors Project - 2002-2006

Topic A:
Design and synthesis of a new type of non-proteic antigen like activators of Tγδ lynphocytes

Topic B:
Design and synthesis of new gelatinases (MMP-2 MMP-9) inhibitors

Partnerships :

Funding Schemes:
Ministero dell’Istruzione, dell’Universita e della Ricerca

Funding Schemes

Research Projects developed thanks to financial support of the following funding schemes: